Compare Neurocrine Biosciences Inc (NBIX) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs TotalEnergies SE — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while TotalEnergies SE trades at $87.24 (market cap $191.82B). The key difference: TotalEnergies SE is far larger — about 13.4× Neurocrine Biosciences Inc's market cap, and TotalEnergies SE pays a 4.93% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and TotalEnergies SE for 90 Days on average.
| NBIX | TTE | |
|---|---|---|
Market Cap | $14.36B | $191.82B |
Volume | 1,237,180 | 3,311,339 |
Sector | Health | Energy |
52-Week High | $185.50 | $93.60 |
52-Week Low | $123.10 | $57.39 |
Typical Hold Time | 23 Days | 90 Days |
Enterprise Value | $14.37B | $222.81B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
TotalEnergies (TTE) trades at $84.23, up 0.3% on the day, with a bearish technical signal from moving averages but recent earnings beats in Q1 and Q2 2026. The stock trades at attractive valuations with a P/E of 10.77 and P/S of 0.96, supported by a 9.08% net income margin. Recent news highlights a $10 billion investment plan in Argentina and a strategic focus on boosting cash flow and dividends through 2030.
The outlook is positive given analyst consensus targets of $95.33 and strong buy ratings (55.88%), though risks include declining revenue trends from 2022-2025 and exposure to oil price volatility. The company's shareholder returns via dividends and buybacks provide support, but investors should monitor execution of growth initiatives amid energy market uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
